Pharmacokinetics of a low molecular weight heparin [Fragmin®] in young and elderly subjects
- 1 June 1992
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 66 (5) , 603-607
- https://doi.org/10.1016/0049-3848(92)90315-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.Journal of Clinical Investigation, 1987
- Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteersThrombosis Research, 1986
- Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administrationThrombosis Research, 1985
- Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparinThrombosis Research, 1981
- HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPYThe Lancet, 1977
- Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin IIIThrombosis Research, 1977
- Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtrationThrombosis Research, 1976
- Efficacy and Toxicity of Heparin in Relation to Age and SexNew England Journal of Medicine, 1968